Abbott: Kevin T. Conroy acquires 318 share-linked units
The units are credited for director fees, track Abbott stock returns, and are generally paid in cash at age 65 or upon board retirement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Abbott Laboratories (ABT) director Kevin T. Conroy acquired 318 Stock Equivalent Units on September 30, 2026, at a reported price of $98.83 per share. His reported balance afterward was 551 Stock Equivalent Units, including units acquired through a dividend reinvestment feature. The units represent director fees credited to a grantor trust and earn the same return as if the fees were invested in Abbott stock; payment is generally in cash at age 65 or upon retirement from the board.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Equivalent Units F1, F2 | 318 | $98.83 | $31K |
Footnotes (2)
- F1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.
- F2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Key Figures
Key Terms
Stock Equivalent Units financial
grantor trust financial
dividend reinvestment feature financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Abbott (ABT) Stock Equivalent Units did Kevin T. Conroy acquire?
AI-generated analysis. How Rhea-AI works. Not financial advice.